Table of Contents Table of Contents 3 List of Tables 5 List of Figures 5 Section 1 - About the Company 6 Generex Biotechnology Corp - Key Facts 6 Generex Biotechnology Corp - Key Employees 7 Generex Biotechnology Corp - Key Employee Biographies 8 Generex Biotechnology Corp - Major Products and Services 9 Generex Biotechnology Corp - History 10 Generex Biotechnology Corp - Company Statement 13 Generex Biotechnology Corp - Locations And Subsidiaries 15 Head Office 15 Other Locations & Subsidiaries 15 Section 2 – Company Analysis 16 Company Overview 16 Generex Biotechnology Corp - Business Description 17 Generex Biotechnology Corp - SWOT Analysis 18 SWOT Analysis - Overview 18 Generex Biotechnology Corp - Strengths 18 Generex Biotechnology Corp - Weaknesses 19 Generex Biotechnology Corp - Opportunities 20 Generex Biotechnology Corp - Threats 21 Generex Biotechnology Corp - Key Competitors 22 Section 3 – Company Financial Ratios 23 Financial Ratios - Capital Market Ratios 23 Financial Ratios - Annual Ratios 24 Performance Chart 26 Financial Performance 26 Financial Ratios - Interim Ratios 27 Financial Ratios - Ratio Charts 28 Section 4 – Company’s Lifesciences Financial Deals and Alliances 29 Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29 Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30 Generex Biotechnology Corp, Recent Deals Summary 31 Section 5 – Company’s Recent Developments 32 Nov 29, 2018: Generex to acquire 51% stake in Olaregen Therapeutix 32 Nov 15, 2018: Generex announces appointment of executive management team 33 Oct 29, 2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer 35 Oct 29, 2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer 37 Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 39 Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 40 Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 41 Oct 12, 2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions 42 Oct 05, 2018: Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program 43 Oct 05, 2018: Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program 46 Section 6 – Appendix 49 Methodology 49 Ratio Definitions 49 About GlobalData 53 Contact Us 53 Disclaimer 53

List of Tables Generex Biotechnology Corp, Key Facts 6 Generex Biotechnology Corp, Key Employees 7 Generex Biotechnology Corp, Key Employee Biographies 8 Generex Biotechnology Corp, Major Products and Services 9 Generex Biotechnology Corp, History 10 Generex Biotechnology Corp, Subsidiaries 15 Generex Biotechnology Corp, Key Competitors 22 Generex Biotechnology Corp, Ratios based on current share price 23 Generex Biotechnology Corp, Annual Ratios 24 Generex Biotechnology Corp, Annual Ratios (Cont...1) 25 Generex Biotechnology Corp, Interim Ratios 27 Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29 Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30 Generex Biotechnology Corp, Recent Deals Summary 31 Currency Codes 49 Capital Market Ratios 49 Equity Ratios 50 Profitability Ratios 50 Cost Ratios 51 Liquidity Ratios 51 Leverage Ratios 52 Efficiency Ratios 52List of Figures Generex Biotechnology Corp, Performance Chart (2014 - 2018) 26 Generex Biotechnology Corp, Ratio Charts 28 Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29 Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

Sernova Corp Novo Nordisk AS Novavax Inc Merck & Co Inc MedImmune, Inc. GlaxoSmithKline Plc GeneNews Ltd Eli Lilly and Co Aptose Biosciences Inc Apotex Inc Ambrilia Biopharma Inc